Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Becton, Dickinson and Company

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an update. BCAL Diagnostics has moved to reshape the board of fellow ASX-listed diagnostics fi...

BCAL Diagnostics pushes for board shake‑up at Genetic Signatures after lifting stake

BCAL Diagnostics Limited ( ($AU:BDX) ) has shared an announcement. BCAL Diagnostics reported FY26 progress highlighting commercial uptake of its BR...

BCAL Diagnostics Builds Early Cancer Detection Platform as Test Uptake Grows

Analysts fell to the sidelines weighing in on Cytokinetics (CYTK) and Becton Dickinson (BDX) with neutral ratings, indicating that the experts are ...

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Becton Dickinson (BDX)

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an announcement. BCAL Diagnostics has lodged its latest corporate governance statement for the...

BCAL Diagnostics Files Updated Corporate Governance Statement with ASX

The latest announcement is out from BCAL Diagnostics Limited ( ($AU:BDX) ). BCAL Diagnostics reported a 10% decline in revenue to $2.55 million for...

BCAL Diagnostics widens early cancer platform as losses deepen and balance sheet weakens

BCAL Diagnostics Limited ( ($AU:BDX) ) has issued an update. BCAL Diagnostics has lifted its stake in molecular diagnostics firm Genetic Signatures...

BCAL Diagnostics boosts Genetic Signatures stake to deepen diagnostics platform

BCAL Diagnostics Limited ( ($AU:BDX) ) has issued an update. BCAL Diagnostics Limited has notified the market of the issue of 1,000,000 unquoted co...

BCAL Diagnostics Issues 1 Million Unquoted Convertible Notes

In a report released today, Travis Steed from Bank of America Securities maintained a Hold rating on Becton Dickinson, with a price target of $185....

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BDX	$184.74	-1.54%	1.44M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BDX	$184.74	-1.5%	1.44M
3
4
5
6

BDX

Get Becton, Dickinson and Company Data in Excel

Get Becton, Dickinson and Company Data in Excel